Stock ACOU ACOUSORT AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials AcouSort AB

Equities

ACOU

SE0009189608

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:23:04 2024-04-26 am EDT 		5-day change 1st Jan Change
10.35 SEK +1.47% Intraday chart for AcouSort AB +2.99% -33.44%
Apr. 02 AcouSort AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 AcouSort Raises Nearly SEK25 Million from Rights Offering MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 82.14 98.36 271.6 338 196.2 231.8
Enterprise Value (EV) 1 66.6 93.26 263.5 306.5 161.8 207.8
P/E ratio -9.17 x -10.2 x -34 x -27.7 x -14.2 x -12.1 x
Yield - - - - - -
Capitalization / Revenue 76.5 x 32.3 x 39.8 x 56.7 x 22.9 x 22 x
EV / Revenue 62 x 30.7 x 38.6 x 51.4 x 18.8 x 19.7 x
EV / EBITDA -7.46 x -9.71 x -34.1 x -26.6 x -12 x -12.4 x
EV / FCF -15.8 x -13.7 x -46.3 x -39.6 x 20.9 x -7.83 x
FCF Yield -6.31% -7.31% -2.16% -2.53% 4.8% -12.8%
Price to Book 5.27 x 16.6 x 28.3 x 10.2 x 10.4 x 9.6 x
Nbr of stocks (in thousands) 10,017 10,017 11,316 13,202 13,202 14,904
Reference price 2 8.200 9.820 24.00 25.60 14.86 15.55
Announcement Date 5/27/19 5/26/20 4/14/21 4/13/22 3/28/23 4/2/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1.074 3.041 6.823 5.959 8.585 10.55
EBITDA 1 -8.925 -9.6 -7.716 -11.52 -13.43 -16.7
EBIT 1 -8.971 -9.646 -7.814 -12.15 -14.35 -17.49
Operating Margin -835.29% -317.2% -114.52% -203.96% -167.14% -165.73%
Earnings before Tax (EBT) 1 -8.96 -9.657 -7.978 -12.2 -13.78 -17.09
Net income 1 -8.96 -9.657 -7.978 -12.2 -13.78 -17.09
Net margin -834.26% -317.56% -116.93% -204.73% -160.51% -161.97%
EPS 2 -0.8945 -0.9641 -0.7050 -0.9241 -1.044 -1.285
Free Cash Flow 1 -4.203 -6.819 -5.686 -7.742 7.758 -26.53
FCF margin -391.33% -224.24% -83.34% -129.93% 90.36% -251.45%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/27/19 5/26/20 4/14/21 4/13/22 3/28/23 4/2/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 15.5 5.1 8.12 31.5 34.4 24
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -4.2 -6.82 -5.69 -7.74 7.76 -26.5
ROE (net income / shareholders' equity) -92.1% -89.8% -103% -57.3% -53.3% -79.3%
ROA (Net income/ Total Assets) -50.1% -47.3% -46.1% -30.5% -23% -28.8%
Assets 1 17.89 20.4 17.32 39.94 59.79 59.42
Book Value Per Share 2 1.560 0.5900 0.8500 2.500 1.440 1.620
Cash Flow per Share 2 1.550 0.5100 0.7200 2.390 2.610 1.610
Capex - 0.09 1.15 0.57 0.38 0.21
Capex / Sales - 2.89% 16.85% 9.58% 4.45% 2.02%
Announcement Date 5/27/19 5/26/20 4/14/21 4/13/22 3/28/23 4/2/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACOUSORT AB Stock AcouSort AB
-33.44% 14.1M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACOU Stock
  4. Financials AcouSort AB